Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Curtis NJ, Mooney L, Hopcroft L, Michopoulos F, Whalley N, Zhong H, Murray C, Logie A, Revill M, Byth KF, Benjamin AD, Firth MA, Green S, Smith PD, Critchlow SE.

Oncotarget. 2017 May 25;8(41):69219-69236. doi: 10.18632/oncotarget.18215. eCollection 2017 Sep 19.

2.

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.

Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, Davies BR, Huszar D, Byth KF.

Oncotarget. 2016 Feb 23;7(8):9163-74. doi: 10.18632/oncotarget.7036.

3.

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.

Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer C, Byth KF.

Oncotarget. 2014 Jul 15;5(13):4990-5001.

4.

Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol.

Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J, Gu RF, Roth M, Toader D, Saeh JC, Chen H.

ACS Chem Biol. 2013 Mar 15;8(3):643-50. doi: 10.1021/cb3005897. Epub 2013 Jan 7.

PMID:
23272696
5.

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.

Byth KF, Thomas A, Hughes G, Forder C, McGregor A, Geh C, Oakes S, Green C, Walker M, Newcombe N, Green S, Growcott J, Barker A, Wilkinson RW.

Mol Cancer Ther. 2009 Jul;8(7):1856-66. doi: 10.1158/1535-7163.MCT-08-0836. Epub 2009 Jun 9.

6.

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.

Jones CD, Andrews DM, Barker AJ, Blades K, Byth KF, Finlay MR, Geh C, Green CP, Johannsen M, Walker M, Weir HM.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. doi: 10.1016/j.bmcl.2008.10.075. Epub 2008 Oct 22.

PMID:
18986805
7.

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.

Anderson M, Andrews DM, Barker AJ, Brassington CA, Breed J, Byth KF, Culshaw JD, Finlay MR, Fisher E, McMiken HH, Green CP, Heaton DW, Nash IA, Newcombe NJ, Oakes SE, Pauptit RA, Roberts A, Stanway JJ, Thomas AP, Tucker JA, Walker M, Weir HM.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5487-92. doi: 10.1016/j.bmcl.2008.09.024. Epub 2008 Sep 10.

PMID:
18815031
8.

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S.

Clin Cancer Res. 2007 Jun 15;13(12):3682-8.

9.

The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor.

Byth KF, Geh C, Forder CL, Oakes SE, Thomas AP.

Mol Cancer Ther. 2006 Mar;5(3):655-64.

11.

Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.

Byth KF, Cooper N, Culshaw JD, Heaton DW, Oakes SE, Minshull CA, Norman RA, Pauptit RA, Tucker JA, Breed J, Pannifer A, Rowsell S, Stanway JJ, Valentine AL, Thomas AP.

Bioorg Med Chem Lett. 2004 May 3;14(9):2249-52.

PMID:
15081018
12.

Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.

Byth KF, Culshaw JD, Green S, Oakes SE, Thomas AP.

Bioorg Med Chem Lett. 2004 May 3;14(9):2245-8.

PMID:
15081017
13.

Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.

Anderson M, Beattie JF, Breault GA, Breed J, Byth KF, Culshaw JD, Ellston RP, Green S, Minshull CA, Norman RA, Pauptit RA, Stanway J, Thomas AP, Jewsbury PJ.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3021-6.

PMID:
12941325
14.

Aberrant TCR-mediated signaling in CD45-null thymocytes involves dysfunctional regulation of Lck, Fyn, TCR-zeta, and ZAP-70.

Stone JD, Conroy LA, Byth KF, Hederer RA, Howlett S, Takemoto Y, Holmes N, Alexander DR.

J Immunol. 1997 Jun 15;158(12):5773-82.

PMID:
9190928
15.

T-cell antigen receptor signal transduction in CD45-/- thymocytes.

Stone JD, Howlett S, Byth KF, Holmes N, Alexander DR.

Biochem Soc Trans. 1997 May;25(2):302S. No abstract available.

PMID:
9191346
16.

Tyrosine phosphatases in T-cell development and signalling.

Conroy LA, Stone JD, Frearson JA, Byth KF, Howlett S, Holmes N, Alexander DR.

Biochem Soc Trans. 1997 May;25(2):445-51. Review. No abstract available.

PMID:
9191133
17.

Defective depletion of CD45-null thymocytes by the Staphylococcus aureus enterotoxin B superantigen.

Conroy LA, Byth KF, Howlett S, Holmes N, Alexander DR.

Immunol Lett. 1996 Dec;54(2-3):119-22.

PMID:
9052865
18.

Supplemental Content

Support Center